Cipla
| Cipla Limited
|
|
|---|---|
 |
|
| legal form | Corporation |
| ISIN | INE059A01026 |
| founding | 1935 |
| Seat |
Mumbai , Maharashtra India
|
| management |
|
| Number of employees | 23,043 |
| sales | 146.3 billion INR 2.117 billion EUR |
| Branch | pharmacy |
| Website | www.cipla.com |
| As of March 31, 2017 | |
Cipla (formerly The Chemical, Industrial & Pharmaceutical Laboratories ) is a pharmaceutical company from India with headquarters in Mumbai .
history
Cipla was founded in 1935 by Khwaja Abdul Hamied (1898–1972). During the Second World War, the company produced quinine , emetine and nikethamide . In 1970, the Indian patent system was relaxed by Indira Gandhi , which made the rise of the Indian generics industry possible in the first place. After his father's death, his son Yusuf Hamied (* 1936 in Vilnius ) took over the company in 1972 . In 1991, Cipla manufactured its first HIV drug with the active ingredient zidovudine (AZT). Initially, however, the company struggled to find a buyer for it.
activity
Cipla produced drugs from a variety of drug classes ( antibiotics , analgesics , cardiovascular drugs, gastrointestinal agents, etc.), veterinary drugs, raw materials for drug manufacture ( mass-produced ) as well as pesticides and pesticides . The total of 2,000 products are manufactured for the local and international market. In the production of pharmaceuticals, Cipla partially ignores existing patents of the original manufacturers, but without breaking Indian or international law; The legal basis for the production and sale of patented drugs is the TRIPS agreement of the WTO .
Cipla is the third largest pharmaceutical company in India and the third largest generics manufacturer in South Africa. The company has a special focus on drugs for respiratory diseases and is one of the largest manufacturers of inhalers.
The medicinal substances (APIs) are manufactured in Kurkumbh near Pune , Patalganga near Kandhar and in Bangalore .
HIV / AIDS preparations
Cipla became internationally known for the manufacture of inexpensive HIV drugs , the pharmaceutical quality of which has been partially tested and confirmed by the WHO . HIV / AIDS is treated with a combination of at least three different antiretroviral drugs ( highly active antiretroviral therapy , HAART). Cipla invented the so-called fixed-dose combinations, in which one tablet contains combinations of two or three antiretroviral agents (e.g. lamivudine , stavudine and nevirapine = Triomune ). Such combination products were not available from the original manufacturers during the 1990s because the active ingredients were manufactured by different companies.
With Cipla's HIV drugs, the cost of a standard combination for treating HIV has been reduced to about $ 100 a year.
Web links
Individual evidence
- ^ Board of Directors
- ↑ a b Eighty-First Annual Report 2017
- ↑ converted at the rate on the balance sheet date, March 31, 2017
- ^ A b c Andrew Jack: The man who battled big pharma , Financial Times, March 28, 2008
- ^ A b Sarah Bosley: Big Pharma's worst nightmare , The Guardian, January 26, 2016
- ^ World Trademark Review: Cipla-Novartis - is revocation a reasonable solution? , accessed February 16, 2017
- ↑ a b Cipla Corporate Presentation , date unknown
- ↑ Alexander S. Kekulé: Finally a pill for everyone , Tagesspiegel, May 19, 2004